Login to Your Account



Financings Roundup

Exelixis Adds $165M to Cancer Drug Development

By Mari Serebrov


Friday, March 11, 2011
A $165 million underwriting agreement may be the prescription Exelixis Inc. needs to get its cancer candidate, cabozantinib, through clinical development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription